Genprex (GNPX) said Wednesday that it has signed an exclusive license agreement that grants the company a worldwide, exclusive license for the University of Michigan's patent rights for the Reqorsa gene therapy.
The gene therapy is used in combination with ALK-inhibitors to potentially treat ALK-EML4 positive translocated lung cancer.
Price: 1.23, Change: -0.06, Percent Change: -4.51
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments